Coherus Chief: FTC Must Probe Originators’ Anti-Competitive Tactics

26 Jun 2019

• By Aidan Fry

Bundled rebate contracts for biologic brands that are designed to thwart biosimilar competition in the US are anti-competitive practices that deserve Federal Trade Commission action, biosimilar developer Coherus’ chief argues in a newspaper opinion piece.

FTC — The Federal Trade Commission must act on anti-competitive biologics rebate bundling that is stifling biosimilars uptake, Coherus chief Denny Lanfear insists • Source: Shutterstock

Biologics originators are using “a combination of coercive, anti-competitive tactics to box out biosimilars”, an approach that merits investigation by the Federal Trade Commission, Coherus BioSciences'’ president, CEO and chairman Denny Lanfear argues in an opinion piece published this week in the Wall Street Journal.

Arguing that branded biologics firms were being allowed to maintain their monopolies almost a decade after the 2010 Biologics Price...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bridging The Void: How Biocon Biologics Sees The Future Of Biosimilars In Europe

02 Jul 2025

• By Dave Wallace

As Biocon Biologics picks up the latest approvals in Europe for its Stelara biosimilar, Blake Leitch, the firm’s head of Europe, talks to Generics Bulletin about what lies ahead for Biocon and for biosimilars more widely in the region – including tackling the “biosimilar void”.

Where Art Thou Celltrion? Kabi Pushes Past With US Denosumab Launches

02 Jul 2025

• By Dean Rudge

Fresenius Kabi has become the second company to launch US denosumab biosimilars, taking its current biosimilars portfolio up to six products.

One Month Remains To Enter GGB Awards 2025

01 Jul 2025

• By Dave Wallace

With the August 1 deadline looming for entries to the Global Generics & Biosimilars Awards 2025, contenders have just one month left to submit their achievements.

Advanz Claims Cimzia Biosimilar In Europe Following Alvotech-Xbrane Deal

01 Jul 2025

• By Dean Rudge

A proposed biosimilar to one of the lesser spoken about monoclonal antibodies for inflammatory conditions, UCB Pharma’s Cimzia, is the latest candidate to join the significant commercial partnership between Alvotech and Advanz Pharma.

One Month Remains To Enter GGB Awards 2025

01 Jul 2025

• By Dave Wallace

With the August 1 deadline looming for entries to the Global Generics & Biosimilars Awards 2025, contenders have just one month left to submit their achievements.